Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathy Robinson

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Biomed Research International|May 28, 2024
Loss of RAB25 Cooperates with Oncogenes in the Transformation of Human Mammary Epithelial Cells (HMECs) to Give Rise to Claudin-Low TumorsPooja Joshi, Vijayalakshmi Ayyagari, Samikshya Kandel, et al.
International Journal of Environmental Research and Public Health|March 25, 2022
Consequences of Structural Urbanism: Urban-Rural Differences in Cancer Patients' Use and Perceived Importance of Supportive Care Services from a 2017-2018 Midwestern SurveyMarquita W Lewis-Thames, Patricia Fank, Michelle Gates, et al.
Cancer Chemotherapy and Pharmacology|July 26, 2013
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancerKrishna Rao, Sini Kalapurakal, Pratima Chalasani, et al.
Life (Basel, Switzerland)|April 23, 2022
Identification of Somatic Mitochondrial DNA Mutations, Heteroplasmy, and Increased Levels of Catenanes in Tumor Specimens Obtained from Three Endometrial Cancer PatientsMatthew J Young, Ravi Sachidanandam, Dale B Hales, et al.
Frontiers in Oncology|March 14, 2022
AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot StudyZhe Cao, Kristin Delfino, Vivek Tiwari, et al.
Oncotarget|July 14, 2020
Renal cell tumors convert natural killer cells to a proangiogenic phenotypeYue Guan, Christopher B Chambers, Taylor Tabatabai, et al.
World Journal of Urology|May 9, 2021
Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatmentShaheen Alanee, Sherjeel Sana, Ahmed El-Zawahry, et al.
Sleep Health|November 13, 2022
The Emergency Medical Services Sleep Health Study: A cluster-randomized trialP Daniel Patterson, Sarah E Martin, Bridget N Brassil, et al.
BMJ Open|January 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancerUma Anne Mukherjee, Helen Hockings, Nicholas Counsell, et al.
Clinical Genitourinary Cancer|March 30, 2024
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin TreatmentJazzmyne Montgomery, Daniel Lybbert, Sherjeel Sana, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Biomed Research International|May 28, 2024
Loss of RAB25 Cooperates with Oncogenes in the Transformation of Human Mammary Epithelial Cells (HMECs) to Give Rise to Claudin-Low TumorsPooja Joshi, Vijayalakshmi Ayyagari, Samikshya Kandel, et al.
International Journal of Environmental Research and Public Health|March 25, 2022
Consequences of Structural Urbanism: Urban-Rural Differences in Cancer Patients' Use and Perceived Importance of Supportive Care Services from a 2017-2018 Midwestern SurveyMarquita W Lewis-Thames, Patricia Fank, Michelle Gates, et al.
Cancer Chemotherapy and Pharmacology|July 26, 2013
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancerKrishna Rao, Sini Kalapurakal, Pratima Chalasani, et al.
Life (Basel, Switzerland)|April 23, 2022
Identification of Somatic Mitochondrial DNA Mutations, Heteroplasmy, and Increased Levels of Catenanes in Tumor Specimens Obtained from Three Endometrial Cancer PatientsMatthew J Young, Ravi Sachidanandam, Dale B Hales, et al.
Frontiers in Oncology|March 14, 2022
AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot StudyZhe Cao, Kristin Delfino, Vivek Tiwari, et al.
Oncotarget|July 14, 2020
Renal cell tumors convert natural killer cells to a proangiogenic phenotypeYue Guan, Christopher B Chambers, Taylor Tabatabai, et al.
World Journal of Urology|May 9, 2021
Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatmentShaheen Alanee, Sherjeel Sana, Ahmed El-Zawahry, et al.
Sleep Health|November 13, 2022
The Emergency Medical Services Sleep Health Study: A cluster-randomized trialP Daniel Patterson, Sarah E Martin, Bridget N Brassil, et al.
BMJ Open|January 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancerUma Anne Mukherjee, Helen Hockings, Nicholas Counsell, et al.
Clinical Genitourinary Cancer|March 30, 2024
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin TreatmentJazzmyne Montgomery, Daniel Lybbert, Sherjeel Sana, et al.
Pageof 5